Multiple Myeloma: post-ASCT Consolidation
Post-autologous stem cell transplant (ASCT) multiple myeloma patients face high relapse rates, with limited safe therapeutic options – our NK cell therapy is intended to boost immune recovery, deepen remissions, and drive cures in this setting.
Advanced Bladder Cancer: Combination w/ Avelumab
Despite platinum chemo and avelumab (αPD-L1) maintenance, most advanced bladder cancer patients relapse quickly – creating a clear opportunity for NOK’s NK cells to boost PD-L1 response, extend survival, and drive cures in this setting.
